The report contains detailed characteristics of distribution on the
pharmaceutical market in Russia and Ukraine. We have analysed four main
segments within distribution in each country: pharmacy distribution, wholesale
distribution, online sales and non-pharmacy sales. The description includes
main features of the segment, profiles of largest players, and the most
important legal regulations affecting the segment. Comparative analyses of
individual segments in particular countries have also been presented.
Key topics discussed
- Number of pharmacy outlets in individual countries
- Number of pharmacy outlets owned by pharmacy chains in individual countries
- Profiles of the largest pharmacy chains in individual countries
- Comparative analysis of pharmacy distribution in individual countries:
number of pharmacies, ratio of population to number of pharmacies
- Number of wholesalers in individual countries
- Profiles of the largest pharmaceutical wholesalers in individual
- Number of wholesale warehouses per pharmacy in individual countries
- Comparative analysis of wholesale distribution in individual countries:
number of warehouses, concentration of market players
- Regulations regarding non-pharmacy sales of medicines in individual
- Regulations regarding mail-order sales of medicines in individual countries
- complex analysis of distribution on the pharmaceutical market
- four key segments covered
- profiles of the largest players and informaion on their financial
The report answers the following questions
- What is the ratio of population to number of pharmacies?
- Which countries are to take initiatives to stop the number of pharmacies
- What trends and events have been the most important for distribution in
- What expected trends and events are the most important for distribution in
- In which CE country does the wholesale distribution segment demonstrate
the highest degree of concentration?
...and many more!
When will the report prove useful?
- Anyone operating on the Russian or Ukrainian pharmaceutical market
- Anyone considering entering those pharmaceutical markets
- Anyone planning their corporate strategy
- Anyone analysing market competition
- Anyone investigating Russian and Ukrainian market's investment potential
- Anyone gauging theopportunities for acquisition on the Russian and
Who is this report for?
- Pharma companies
- Logistics firms
- Pharmacy chains - domestic and foreign
- Pharmaceutical distributors (wholesalers) - domestic and foreign
- Foreign firms investing in the Russian and Ukrainian pharmaceutical sector
- Consulting, research and analysis firms
- Government institutions, embassies
- Chambers of commerce, industry bodies
- Universities, academic institutions
- Financial institutions (banks, brokerage houses, investment funds)
Companies mentioned in this report:
Protek CV, Katren, SIA International, Rosta, Alliance Healthcare., A5, Apteki
36,6, Implozia, Rigla, Raduga, Pharmacor, Pharmaimpex, Starij Lekar, BaDM,
Optima-Pharm, Alba Ukraine, VVS, Fra-M., Pharmacia (Lugansk), Med-Service,
Poltavapharm, Pharmacia Kiev, Ukrainian Pharmacy Holding, Falbi, Arnika,
Extract from this report
- The maximum retail markup on drugs on the national list of essential drugs
and medical products is 25% (10% on drugs purchased in full or in part through
budgetary funds) in Ukraine.
- The number of pharmacy outlets in Ukraine fluctuated during the past
decade and stood at 22,072 in June 2011. This included 13,655 pharmacies,
5,420 drugstores and 2,997 pharmacy kiosks.
- Retail trading in medicines in Russia may be carried out only by
healthcare entities licensed for pharmaceutical activity, along with their
separate subdivisions (outpatient clinics, obstetrics stations, general
medical centres) located in rural areas in which there are no pharmacy outlets.
Market commentary by expert
Russia and Ukraine are extremely attractive markets for pharmaceutical
companies due to their large populations, low saturation of the market, its
rapid development, and widespread unhealthy lifestyles that lead to high
incidence of various diseases. The markets are also quite difficult, as
legislation is vague and business climate unique. Our report will help
companies wanting to invest in the region, as well as those already operating
on the market, to understand and plan strategies for selling their products in
Russia and Ukraine.